Updated
Updated · Retraction Watch · Jul 28
Nature, Shanghai Jiao Tong Probe Gene-Editing Paper After 6-Year-Old's Death and $860,000 Funding
Updated
Updated · Retraction Watch · Jul 28

Nature, Shanghai Jiao Tong Probe Gene-Editing Paper After 6-Year-Old's Death and $860,000 Funding

3 articles · Updated · Retraction Watch · Jul 28

Summary

  • Nature placed an editors’ note on the February paper and opened an investigation after concerns surfaced over undisclosed funding, the girl’s death and the study’s data.
  • The paper described only preclinical work for a treatment for Snijders Blok-Campeau syndrome, but the family of a 6-year-old patient paid $860,000 to support that work before she died seven days after receiving the therapy.
  • Nature said the submitted manuscript mentioned no planned human trial, while outside experts cited in the report also questioned some efficacy results presented in the study.
  • Shanghai Jiao Tong University School of Medicine has separately formed a special task force to investigate the incident at Xinhua Hospital, widening scrutiny of the case beyond the journal.

Insights

How did a fatal, privately funded gene-editing trial on a child remain hidden during publication in a top scientific journal?
Why were severe organ damage warnings from animal trials allegedly ignored before injecting a child with an unproven CRISPR therapy?

Fatal Gene Therapy in China: The Hidden Death of "Mei," $800,000 Parental Payment, and the Global Fallout for Scientific Ethics

Overview

In March 2025, neuroscientist Zilong Qiu and his team in China gave a high-dose experimental gene-editing therapy to a six-year-old girl known as 'Mei', despite preclinical animal trials warning of severe organ damage. The excessive viral dose caused a fatal immune reaction, leading to Mei’s death within a week. Instead of reporting the tragedy, Qiu’s team published a paper omitting Mei’s case and her family’s funding. This cover-up was exposed in July 2026, prompting a formal investigation and calls for stricter oversight, highlighting serious ethical and regulatory failures in China’s gene-editing research.

...